<DOC>
	<DOCNO>NCT00189917</DOCNO>
	<brief_summary>The purpose study gather information safety immunogenicity investigational smallpox vaccine population atopic disorder .</brief_summary>
	<brief_title>Safety , Tolerability Immune Response IMVAMUNE ( MVA-BN ) Smallpox Vaccine Patients With Atopic Disorders</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>All subject Age 1840 . Read , sign date informed consent . Women childbearing potential must use acceptable method contraception Group 1 : Healthy subject No history atopic dermatitis documented patient file No active atopic dermatitis No atopic disorder asthma allergic rhinitis . Prick test without clinical significance IgE within normal range Group 2 : Subjects history atopic dermatitis Group 3 : Subjects mild active atopic dermatitis SCORAD 1 15 . Group 4 : Subjects mild allergic rhinitis At least one active allergic rhinitis phase last year . Known suspect history smallpox vaccination typical vaccinia scar . Positive test result MVA specific ELISA screening . Positive result HIV HCV antibody test screening . Surface antigen Hepatitis B Virus ( HBsAg ) positive screening . Pregnant breastfeed woman . Positive pregnancy test screen and/or within 24 hour prior vaccination . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) institutional upper limit normal . Positive urine glucose dipstick urine analysis . Inadequate renal function define serum creatinine institutional upper limit normal ; urine protein &gt; 30 mg/dl trace proteinuria ( urine analysis dipstick ) ; calculate creatinine clearance &lt; 80 ml/min . Electrocardiogram ( ECG ) clinical significance . Hemoglobin &lt; 11 g/dl ; White blood cell less 2,500 11,000/mm3 ; Platelets le 140,000/mm3 . Uncontrolled serious infection i.e . respond antimicrobial therapy . History serious medical condition , opinion investigator would compromise safety subject . History active autoimmune disease . Known suspected impairment immunologic function include , limited , clinically significant liver disease ; diabetes mellitus ; moderate severe kidney impairment . History malignancy . History clinical manifestation clinically significant mental illness haematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder . Any condition might interfere study objective . History immunodeficiency . History myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , heart condition care doctor . Three follow risk factor : High blood pressure , high blood cholesterol , diabetes mellitus high blood sugar , first degree relative heart condition age 50 , smoke cigarette . History chronic alcohol abuse and/or intravenous drug abuse . History allergic reaction likely exacerbate component vaccine . History anaphylaxis severe allergic reaction . Acute disease ( illness without fever ) time enrollment . Any vaccination within period start 30 day prior administration vaccine end study conclusion . Chronic administration immunosuppressant immunemodifying drug . Post organ transplant subject whether receive chronic immunosuppressive therapy . Administration plan administration immunoglobulin and/or blood Use investigational nonregistered drug . Blood donation 8 week advance study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>